Exhibit 99.1 Ocugen Provides Business Update with Second Quarter 2024 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET • Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial • OCU410 preliminary safety and ef icacy data expected later this year • Expanded access program approved for OCU400 • $32.6 million net cash from underwritten public of ering of common stock MALVERN, Pa., August 8, 2024 (GLOBE NEWSWIRE) – Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechno ...

Ocugen, Inc. (NASDAQ:OCGN) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Tiffany Hamilton - Head of Corporate Communications Shankar Musunuri - Chairman of the Board, CEO & Co-founder Michael Breininger - Corporate Controller Huma Qamar - Chief Medical Officer Conference Call Participants Sean Lee - H.C. Wainwright Robert LeBoyer - Noble Capital Markets Janani Sundararajan - Chardan Capital Markets Operator Good morning, and welcome to Ocugen's Second Quarter 2024 Financial ...

Table of Contents ` Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share OCGN The Nasdaq Stock Market LLC (The Nasdaq Capital Market) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the ...

MALVERN, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it has received notification from FDA to begin its expanded access program (EAP) for the treatment of adult patients, aged 18 and older, with retinitis pigmentosa (RP) with OCU400—a modifier gene therapy product candidate. "Each clinical milestone achieved by OC ...

MALVERN, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it has received notification from FDA to begin its expanded access program (EAP) for the treatment of adult patients, aged 18 and older, with retinitis pigmentosa (RP) with OCU400—a modifier gene therapy product candidate. "Each clinical milestone achieved by OC ...

MALVERN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the closing of its previously announced underwritten public offering of 30,434,783 shares of its common stock. Each share of common stock was sold at a price to the public of $1.15 per share. The gross proceeds to the Company from the offering were approximately $35 million, before deducting und ...

MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the pricing of its underwritten public offering of 30,434,783 shares of its common stock at an offering price of $1.15 per share of common stock for gross proceeds of $35 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen ...

MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the pricing of its underwritten public offering of 30,434,783 shares of its common stock at an offering price of $1.15 per share of common stock for gross proceeds of $35 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen ...

MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it has commenced an underwritten public offering (the "offering") of its common stock. In addition, Ocugen expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock to be sold in the public offering at the pub ...

Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site. Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact ...